Trial Profile

Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belatacept (Primary) ; Antithymocyte globulin; Everolimus; Methylprednisolone; Mycophenolate mofetil; Prednisone; Tacrolimus
Indications Renal transplant rejection
Focus Therapeutic Use
Sponsors Bristol-Myers Squibb

Most Recent Events

28 May 2021 Status changed from discontinued to completed.
03 Jun 2020 Results exploring the use of of belatacept in combination with immunosuppressive agents other than those in the approved regimen would lead to AR rates comparable to those seen with CNI-based therapy presented at the 2020 American Transplant Congress
03 Jun 2020 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com